Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 17, 2007

Cepheid and bioMerieux Partner on Sepsis Test

  • Cepheid and bioMerieux will together develop and commercialize an innovative line of sepsis test products on the GeneXpert® platform.

    The product menu comprises both bacterial and fungal identification assays as well a series of genetic markers for antibiotic resistance. There is also the potential for hospital-acquired pneumonia applications. 

    Cepheid will be in charge of manufacturing, and bioMerieux will distribute the sepsis assays on an exclusive, worldwide basis.

    In addition, bioMerieux has granted Cepheid a nonexclusive, worldwide license under the Hiramatsu patents on methicillin-resistant staphylococcus aureus (MRSA) for all applications. Cepheid will continue to develop, manufacture, and market MRSA products.



Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »